PRECLINICAL AND CLINICAL ASPECTS OF THE DEVELOPMENT OF BIOMEDICAL CELL PRODUCTS

The article reviews literature data on development and clinical use of biomedical cell products (BCPs) — a new class of medicines which could be approved for distribution and use only after their specific activity and safety have been thoroughly examined at the stage of experimental research. The article describes main characteristics of BCPs approved in the Russian Federation, as well as specific aspects of their formulation and use. It analyses the main stages of preclinical studies (requirements for animal models, testing of general toxicity, immunogenicity, oncogenicity, tumorigenicity, etc.) that do not cover medicine quality evaluation. The article also dwells upon requirements for the clinical stage of BCPs development. It was shown that the choice of clinically relevant efficacy and safety endpoints could be substantiated by respective preclinical data and accumulated experience of the clinical use of medicines for a particular condition.

1. Committee for Advanced Therapies (CAT). European Medicines Agency. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000266.jsp

2. Human cells, tissues, and cellular and tissue-based products. 21CFR1271. U.S. Departament of Health and Human Services. Available from: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=1271&showFR=1

3. Guideline on human cell-based medicinal products. London, 21 May 2008 (EMEA/CHMP/410869/2006). European Medicines Agency. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003894.pdf

4. Guidance for Industry: Preclinical Assessment of Investigational Cellular and Gene Therapy Products. Federal register. Available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM376521.pdf

5. Supotnitsky MV, Elapov AA, Borisevich IV, Klimov VI, Lebedinskaya EV, Mironov AN, et al. Promising methodological approaches to preclinical studies of biomedical cell-based products and their possible quality characteristics. Biopreparations. Prevention, diagnosis, treatment 2015; (1): 36-44 (In Russ.)

6. Reflection paper on classification of advanced therapy medicinal products. 21 May 2015 (EMA/CAT/600280/2010). European Medicines Agency. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/06/WC500187744.pdf

7. Commission regulation (EC) No 668/2009 of 24 July 2009. Official Journal of the European Union. Available from: http://ec.europa.eu/health/files/eudralex/vol-1/reg_2009_668/reg_2009_668_en.pdf

8. Guideline on the minimum quality and non-clinical data for certification of advanced therapy medicinal products. 15 October 2010 (EMA/CAT/486831/2008/corr). European Medicines Agency. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070031.pdf

9. Regulation (EC) No 1394/2007 of the European Parliament and of the Council. Official Journal of the European Union. Available from: http://www.biosafety.be/PDF/1394_2007_EN.pdf

10. Reflection paper on in-vitro cultured chondrocyte containing products for cartilage repair of the knee. London, 08 April 2010 (EMA/CAT/CPWP/568181/2009). European Medicines Agency. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/05/WC500090887.pdf

11. European Medicines Agency. Assessment report. Holoclar. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__Public_assessment_report/human/002450/WC500183405.pdf

12. Cellular, Tissue and Gene Therapies Advisory Commit Rel Links. U.S. Departament of Health and Human Services. Available from: https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/CellularTissueandGeneTherapiesAdvisoryCommittee/default.htm

13. Pyatigorskaya NV, Tulina MA, Aladysheva ZhI, Beregovykh VV. International approaches to the regulation of cell therapy products. Annals of the Russian academy of medical sciences 2013; 68(8): 4-8 (In Russ.)

14. Tkachuk VA. Methodical recommendations for conducting preclinical studies of biomedical cellular products. Moscow: Lomonosov Moscow State University; 2017 (In Russ.)

15. Melnikova EV, Merkulova OV, Chaplenko AA, Merkulov VA. Design of preclinical studies of biomedical cell products: characteristics, key principles and requirements. Biopreparations. Prevention, diagnosis, treatment 2017; 17(3): 133-44 (In Russ.)

16. Order of the Ministry of Health of the Russian Federation of 22.09.2017, No 669n «On approval of the rules of good practice for working with biomedical cellular products» (in Russ.) Available from: http://www.consultant.ru/document/cons_doc_LAW_282104

17. Lewis AM Jr. Regulatory implications of neoplastic cell substrate tumorigenicity. U.S. Food and Drug Administration 2005; 31. Available from: http://slideplayer.com/slide/5673889

18. Clinical Trials. gov. Available from: https://www.clinicaltrials.gov/ct2/home

19. Federal Law of the Russian Federation of 23.06.2016, No. 180-FZ «On Biomedical Cell Products» (In Russ.) Available from: https://rg.ru/2016/06/28/produkti-dok.html

20. Resolution of the Government of the Russian Federation of 25.08.2017, No. 1015 «On the Approval of the Rules for the Accreditation of Medical Organizations for the Right to Conduct Clinical Studies of Biomedical Cell Products» (In Russ.) Available from: http://www.garant.ru/products/ipo/prime/doc/71654384